Zacks Investment Research downgraded shares of SONOVAC BIOTECH (SVA) from NEUTRAL to UNDERPERFORM on May 10, 2012, with a target price of $1.90.
Sonovac Biotech Ltd. specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as hepatitis A and hepatitis B, influenza, "SARS", and avian flu. Sinovac is one of the leading emerging biotechnology companies in China.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SONOVAC BIOTECH (SVA),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment